Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-25-297
Official listed status: posted
Closing information: 2027-11-05 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Official federal synopsis lists an award ceiling of 1,500,000; applicant-level applicability requires full-NOFO review.
Applicant categories in federal synopsis: Native American tribal governments (Federally recognized); Others (see text field entitled "Additional Information on Eligibility" for clarification); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Special district governments; Public and State controlled institutions of higher education; County governments; State governments; For profit organizations other than small businesses; Private institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; City or township governments; Independent school districts; Native American tribal organizations (other than Federally recognized tribal governments)
Federal synopsis
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.